In addition, SMARCA4-mutated NSCLCs are associated with a higher likelihood of negative or low programmed cell death ligand-1 (PD-L1) expression (p =0.03) and higher tumor mutational burden (TMB) as compared to wild-type (WT) cases (p < 0.001) [7,8]. This evidence concerns the gene SMARCA4 and neoplasm.